C12 DAPAGLIFLOZIN INCREASES PAMPK AND REDUCES MYOCARDIAL AND RENAL NF–KB EXPRESSION IN PRECLINICAL MODELS OF SHORT–TERM DOXORUBICIN CARDIOTOXICITY THROUGH MYD–188 AND NLRP3 PATHWAYS
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rosalaura Sabetta(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Renato Franco(Istituto di Chimica Biomolecolare), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelangela Barbieri(University of Campania "Luigi Vanvitelli"), Marco Montella(University of Campania "Luigi Vanvitelli"), Francesco Paolo Zito(Ospedale Antonio Cardarelli)
Cited by 3
Related Papers
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
|Diabetes & Metabolism|2020|138
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108